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Background 
Antiepileptic drugs were frequently used as polytherapy until evidence from a series of 
studies in the late 1970s and early 1980s suggested that patients derive as much benefit from 
monotherapy as polytherapy.[1-3]. Antiepileptic drug polytherapy is increasingly becoming 
popular again and as much as 30-40% of prescriptions to children are polytherapy.[4, 5]. The 
availability of new generation AEDs in the last two decades has encouraged polytherapy. AEDs 
such as lamotrigine, topiramate, levetiracetam, oxcarbazepine, and zonisamide have been 
approved for paediatric use and are recommended mostly as adjuncts or as second-line 
agents.[6] Despite the availability of more AEDs, the prevalence of poorly controlled 
epilepsies still remains the same. About 30% of epilepsies are resistant to treatment.[7] Drug 
resistant epilepsies almost always require polytherapy, but the question of the best treatment 
approach when an initial monotherapy fails is still debatable. 
Rational polytherapy 
Rational polytherapy has been suggested for the treatment of epilepsies. It refers to the use 
of 2 or more drug combinations with different mechanisms of action. The goal is to achieve 
synergistic or supra-additive efficacy. A combination regimen is supra-additive when it 
produces a total effect that is higher than the effects of the sum of individual drugs.   Rational 
polytherapy sometimes aims to attain infra-additive toxicity, such that the component drugs 
in the polytherapy regimen produce a total toxicity less than the sum of the individual 
toxicities.[8] 
Clinical evidence in support of rational polytherapy for epilepsy is sparse. A 1997 multicentre 
European study, involving 347 adults, reported synergism between sodium valproate and 
lamotrigine.[9] Patients given sodium valproate with lamotrigine add-on, had better response 
rate than those given carbamazepine or phenobarbital with add-on lamotrigine. Another 
multicentre cohort study in Spain, showed that lacosamide, a sodium channel blocker, was 
more effective (with a higher seizure freedom rate and clinical response) and better tolerated 
when combined with a non-sodium channel blocker, rather than with another sodium 
channel blocker.[10] Neither of these studies however evaluated monotherapy.  Synergistic 
effects however do not always occur when AEDs with different mechanisms of action are 
combined. Brodie et al, reported that retigabine, a new generation AED which enhances 
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potassium channel activity, combined with sodium channel or non-sodium channel AEDs 
showed similar efficacy and safety.[11]  
Rational polytherapy requires a sound knowledge of the mechanisms of action of AEDs. A 
single AED often has multiple mechanisms of action which makes the choice of appropriate 
combinations challenging.  
Monotherapy or polytherapy in epilepsy management 
In the late 1970s, Reynolds, Shorvon and colleagues conducted a series of studies which 
showed that AED efficacy was higher when optimum concentrations of monotherapy were 
administered to treatment naïve patients. These studies highlighted the fact that polytherapy 
is unnecessary as an initial approach to epilepsy treatment.[2, 3] This shaped the landscape 
of epilepsy management afterwards. Recent studies have also demonstrated relatively 
comparable efficacy and safety profiles for monotherapy and polytherapy. A systematic 
search of databases Medline and EMBASE using search terms:  ‘monotherapy’ and 
‘polytherapy or add-on or adjunct*’ and ‘epilepsy or seizure*’ yielded 6 studies in which 
efficacy and safety of AED monotherapy was compared with polytherapy (Table 1). A  French 
multicentre study, that compared substitution of monotherapy and add-on treatment in 
patients with failed initial monotherapy, did not show any significant difference in seizure 
freedom at 12 months, 50% seizure reduction at 2 months, and adverse effect profiles of the 
two treatment groups.[12] Several other large studies have also reported similar efficacy and 
safety profiles for substituted monotherapy and add-on therapy after failure of initial 
monotherapy.[13, 14] None of the six studies showed significant difference in epilepsy 
control. 
When drugs, especially those that share similar metabolic pathways and mechanisms of 
action are combined, they are likely to interact. In a prospective study, Anderson et al 
reported a significantly higher risk of adverse drug reactions (ADRs) in children receiving 
polytherapy than monotherapy.[15] Aggregated safety reports for lamotrigine in children 
have also shown that the risks of developing most ADRs are lower with monotherapy than 
polytherapy.[16]  Also, supra-additive toxicity is likely with polytherapy involving drugs with 
similar mechanisms of action. For example, combinations of carbamazepine and 
oxcarbazepine, or gabapentin and pregabalin, or the use of different benzodiazepines should 
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usually be avoided. Combinations where the common adverse effects are similar are probably 
best avoided, at least in the long term. The risk of neurotoxicity is higher when lamotrigine is 
added to carbamazepine [17] or when lacosamide is co-prescribed with other sodium channel 
blockers[18], due to pharmacodynamic interactions.  Although phenytoin and phenobarbital 
have different mechanisms, one a sodium channel blocker and the other a gaba-ergic 
potentiator, their pharmacokinetics interact in complex ways making their interaction rather 
unpredictable, this makes it difficult to achieve adequate levels without toxicity.  
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Table 1: Treatment outcome with monotherapy versus polytherapy 
                 Efficacy        Adverse reactions 
Reference Age(yrs) Efficacy outcome Mono Poly P value Mono Poly P value 
†Semah et al, 2014 [12]     18-65 Seizure freedom at 2 months 51% 45% 0.34 - - - 
 50% seizure reduction at 6 months 76% 84% 0.53 - - - 
†Millul et al, 2013 [13]      2-86 Treatment failure 27.2% 25% Ns 29.2% 26.1% Ns 
†Beghi et al, 2003 [14]      2-70 Retention rate at 12 months 55% 65% 0.74 51% 37% 0.07 
Deckers et al,2001 [19]      ≥18 Seizure freedom at 12 months 86% 74% - 22% 14% 0.15 
†Jozwiak et al, 2000 [20]     12-52 50% seizure reduction at 7 months 53% 50% - - - - 
†Kwan and Brodie, 2000 [7]     1-87 Seizure freedom 17% 26% Ns 26% 12% 0.25 
†Substituted monotherapy versus add-on therapy, Ns-not significant 
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Treatment approach to epilepsy 
The goal of treatment is to achieve full seizure control with minimal toxicity. Therefore, it is 
important to balance the benefits and risks when choosing AEDs. It is generally agreed that 
monotherapy should be the initial treatment for newly diagnosed epilepsy in children.[21-23] 
When one AED does not work, a second drug should be introduced while the child is still 
receiving the ineffective drug. All changes in therapy, whether adding or withdrawing an AED 
need to be agreed with the parent and the patient. It is important to consider any possible 
interactions when introducing the new AED. If seizure control is achieved with the new drug, 
a gradual withdrawal of the ineffective AED should be attempted. However, withdrawal of 
the first AED depends on whether it was felt to be partially effective. Also important are its 
adverse effects and how severe a relapse in the epilepsy would be at the time. For example, 
in a 16 year old, the period just before important examinations would not be an ideal time to 
withdraw even a probably ineffective AED. 
If the newly added AED is ineffective at maximum tolerated dose (with a serum level at the 
top of the target range if appropriate) or at a dose well above the maximum recommended 
dose, one of the AEDs should be slowly withdrawn. A new drug could be introduced either at 
the same time (placing the child on 3 AEDs temporarily) or after one has been withdrawn. 
When polytherapy is inevitable  
The cautious delayed withdrawal of a first ineffective AED can be classed a polytherapy, but 
is generally viewed as sensible, even by staunch advocates of ‘mono-therapy’. 
Drug resistant epilepsies 
Polytherapy is inevitable in children with drug resistant epilepsies. The International League 
Against Epilepsy (ILAE) defines drug resistant epilepsy as: ‘failure of adequate trials of two 
tolerated and appropriately chosen and used AED schedules (whether as monotherapies or 
in combination) to achieve sustained seizure freedom’.[24] In children with drug resistant 
epilepsies, it is common practice to sequentially add AEDs to an existing treatment until 
seizure control is achieved. However, it is really important to sequentially withdraw 
ineffective or un-tolerated AEDs, otherwise it is easy to end up with a child on 4 or 5 different 
AEDs the same time. This increases the likelihood of adverse interactions and more severe 
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adverse effects. Sometimes, parents are reluctant to withdraw an AED, but can usually be 
persuaded by knowing that the drug was ineffective and that the epilepsy will vary through 
better and worse patches irrespective of what is done with the ineffective AEDs. Furthermore, 
if the plan leads to a worsening in seizures it can always be reversed. 
Electroclinical syndromes 
There are several electroclinical syndromes, some of which are benign and are easily treated 
or may require no treatment. However, some electroclinical syndromes will almost always 
require polytherapy.  
Infantile Spasms (West syndrome) 
Infantile Spasms not due to tuberous sclerosis are generally treated first-line with either 
hormonal therapy (prednisolone or tetracosactide) or vigabatrin. Vigabatrin is the treatment 
of choice in children with infantile spasm with tuberous sclerosis.  Emerging evidence from a 
recent multicentre trial reported that hormonal therapy and vigabatrin combination produces 
faster clinical response and better seizure freedom than hormonal treatment alone. [25] 
Dravet syndrome 
Sodium valproate or topiramate is the first-line treatment in children with Dravet syndrome. 
However, the seizures are often refractory and adjunctive treatment with clobazam and/or 
stiripentol is usually required.[26] Treatment options are limited because AEDs that target the 
sodium channel, such as lamotrigine, carbamazepine, oxcarbazepine and phenytoin may 
aggravate the seizures,[27] and often produce chorea in Dravet syndrome. However some 
children may in fact benefit from phenytoin. 
Lennox-Gastaut syndrome (LGS) 
Effective treatment options are few and about 75% of children with LGS have drug resistant 
epilepsy.[28] Sodium valproate is often combined with one or two other AEDs, including 
clobazam, or lamotrigine, or rufinamide, or topiramate.[26] 
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Childhood absence epilepsy (CAE) 
CAE usually responds well to treatment with either valproate or ethosuximide, however those 
with onset under 4 or 5 years of age have a more severe version of CAE,[29] and are typically 
unresponsive to the usual treatments. However this refractory “Early Onset CAE” can in some 
cases be well controlled with polytherapy, without adverse effects, even though 3 or 4 AEDs 
are usually needed, e.g. valproate, ethosuximide, lamotrigine or clobazam.[30] 
Conclusion and practical guide 
1. Drug resistant epilepsy is a real challenge and it is easy to over treat with excess doses 
and combinations.  
2. Always have a clear and good reason for using polytherapy. 
3. Avoid 3 or more drugs at a time (except during tailing off) in ambulant patients if at all 
possible. 
4. Remember to withdraw an AED when it is ineffective. 
5. Ensure that all additions and withdrawals of treatment are agreed to by parents and 
patient.  
6. When seizures increase as the dose is reduced, continue tailing it off, unless you are 
convinced the patient would be better off on it. Remember epilepsy waxes and wanes 
unpredictably whatever you do.  
7. Discontinue an AED if a serious ADR occurs, record it and avoid the drug next time in 
that patient. 
8.  Accept that on rare occasions the general advice given here will need to be modified 
and individualised for a specific child at a specific time in their illness. 
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